In vitroactivity of dalbavancin against Gram-positive bacteria isolated from diabetic foot osteomyelitis
- 11 April 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (8) , 2057-2060
Abstract
Background: Diabetic foot infections (DFIs) represent a serious threat to public health because of their frequency and the severity of their consequences, i.e. osteomyelitis and amputation. The management of diabetic foot osteomyelitis (DFOM) requires prolonged antibiotic therapy. In Western countries, Gram-positive bacteria are the most commonly encountered pathogens.Objectives: This study evaluated the in vitro activity of dalbavancin, a novel lipoglycopeptide with extended half-life, recently marketed in Europe for acute bacterial skin and skin structure infections, on a panel of Gram-positive bacteria responsible for DFOM.Methods: Dalbavancin activity was evaluated against a panel of Gram-positive bacterial strains isolated from bone biopsies performed by a trained surgeon among patients with suspected DFOM. MICs were determined using MIC Test Strips (Liofilchem) and confirmed with the EUCAST broth microdilution method. Three other antimicrobial agents (vancomycin, teicoplanin and ceftobiprole) were used as comparators.Results: Dalbavancin showed excellent activity against all Gram-positive bacterial strains tested, including one teicoplanin-resistant Staphylococcus epidermidis isolate. With MIC50 and MIC90 values of 0.047 and 0.094 mg/L, respectively, dalbavancin showed the most potent in vitro activity among antimicrobial agents tested.Conclusions: With its efficacy, good tolerability and unique pharmacokinetic properties, dalbavancin appears to be a promising treatment for DFOM involving Gram-positive bacteria.Keywords
This publication has 20 references indexed in Scilit:
- In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection sourceInternational Journal of Infectious Diseases, 2019
- Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016)International Journal of Antimicrobial Agents, 2018
- Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococciDiagnostic Microbiology and Infectious Disease, 2018
- Diabetic Foot Ulcers and Their RecurrenceNew England Journal of Medicine, 2017
- Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and ResistanceCold Spring Harbor Perspectives in Medicine, 2016
- Staphylococcus aureus Toxins and Diabetic Foot Ulcers: Role in Pathogenesis and Interest in DiagnosisToxins, 2016
- Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive InfectionsInfectious Diseases and Therapy, 2015
- Staphylococcus caprae bone and joint infections: a re-emerging infection?Clinical Microbiology and Infection, 2014
- The Neuropathic Diabetic Foot Ulcer Microbiome Is Associated With Clinical FactorsDiabetes, 2013
- In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot InfectionsAntimicrobial Agents and Chemotherapy, 2006